Intra-individual variability in the neuroprotective and promyelinating properties of conditioned culture medium obtained from human adipose mesenchymal stromal cells.
Growth factors
Mesenchymal stromal cells
Neuroprotection
Remyelination
Secretome
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
11 05 2023
11 05 2023
Historique:
received:
05
08
2022
accepted:
13
04
2023
medline:
15
5
2023
pubmed:
12
5
2023
entrez:
11
5
2023
Statut:
epublish
Résumé
Greater knowledge of mesenchymal stromal cell (MSC)-based therapies is driving the research into their secretome, identified as the main element responsible for their therapeutic effects. The aim of this study is to characterize the individual variability of the secretome of adipose tissue-derived MSCs (adMSCs) with regard to potential therapeutical applications in neurology. adMSCs were isolated from the intact adipose tissue of ten subjects undergoing abdominal plastic surgery or reduction mammoplasty. Two commercial lines were also included. We analyzed the expansion rate, production, and secretion of growth factors of interest for neurological applications (VEGF-A, BDNF, PDGF-AA and AA/BB, HGF, NGF, FGF-21, GDNF, IGF-I, IGF-II, EGF and FGF-2). To correlate these characteristics with the biological effects on the cellular targets, we used individual media conditioned with adMSCs from the various donors on primary cultures of neurons/astrocytes and oligodendrocyte precursor cells (OPCs) exposed to noxious stimuli (oxygen-glucose deprivation, OGD) to evaluate their protective and promyelinating properties, using MSC medium as a control group. The MSC secretome showed significant individual variability within the considered population with regard to PDGF-AA, PDGF-AB/BB, VEGF-A and BDNF. None of the MSC-derived supernatants affected neuron viability in normoxia, while substantial protection by high BDNF-containing conditioned MSC medium was observed in neuronal cultures exposed to OGD conditions. In OPC cultures, the MSC-derived supernatants protected cells from OGD-induced cell death, also increasing the differentiation in mature oligodendrocytes. Neuroprotection showed a positive correlation with VEGF-A, BDNF and PDGF-AA concentrations in the culture supernatants, and an inverse correlation with HGF, while OPC differentiation following OGD was positively correlated to PDGF-AA concentration. Despite the limited number of adMSC donors, this study showed significant individual variability in the biological properties of interest for neurological applications for adMSC secretome, an under-researched aspect which may represent an important step in the translation of MSC-derived acellular products to clinical practice. We also showed the potential protection capability of MSC conditioned medium on neuronal and oligodendroglial lineages exposed to oxygen-glucose deprivation. These effects are directly correlated to the concentration of specific growth factors, and indicate that the remyelination should be included as a primary target in MSC-based therapies.
Sections du résumé
BACKGROUND
Greater knowledge of mesenchymal stromal cell (MSC)-based therapies is driving the research into their secretome, identified as the main element responsible for their therapeutic effects. The aim of this study is to characterize the individual variability of the secretome of adipose tissue-derived MSCs (adMSCs) with regard to potential therapeutical applications in neurology.
METHODS
adMSCs were isolated from the intact adipose tissue of ten subjects undergoing abdominal plastic surgery or reduction mammoplasty. Two commercial lines were also included. We analyzed the expansion rate, production, and secretion of growth factors of interest for neurological applications (VEGF-A, BDNF, PDGF-AA and AA/BB, HGF, NGF, FGF-21, GDNF, IGF-I, IGF-II, EGF and FGF-2). To correlate these characteristics with the biological effects on the cellular targets, we used individual media conditioned with adMSCs from the various donors on primary cultures of neurons/astrocytes and oligodendrocyte precursor cells (OPCs) exposed to noxious stimuli (oxygen-glucose deprivation, OGD) to evaluate their protective and promyelinating properties, using MSC medium as a control group.
RESULTS
The MSC secretome showed significant individual variability within the considered population with regard to PDGF-AA, PDGF-AB/BB, VEGF-A and BDNF. None of the MSC-derived supernatants affected neuron viability in normoxia, while substantial protection by high BDNF-containing conditioned MSC medium was observed in neuronal cultures exposed to OGD conditions. In OPC cultures, the MSC-derived supernatants protected cells from OGD-induced cell death, also increasing the differentiation in mature oligodendrocytes. Neuroprotection showed a positive correlation with VEGF-A, BDNF and PDGF-AA concentrations in the culture supernatants, and an inverse correlation with HGF, while OPC differentiation following OGD was positively correlated to PDGF-AA concentration.
CONCLUSIONS
Despite the limited number of adMSC donors, this study showed significant individual variability in the biological properties of interest for neurological applications for adMSC secretome, an under-researched aspect which may represent an important step in the translation of MSC-derived acellular products to clinical practice. We also showed the potential protection capability of MSC conditioned medium on neuronal and oligodendroglial lineages exposed to oxygen-glucose deprivation. These effects are directly correlated to the concentration of specific growth factors, and indicate that the remyelination should be included as a primary target in MSC-based therapies.
Identifiants
pubmed: 37170115
doi: 10.1186/s13287-023-03344-1
pii: 10.1186/s13287-023-03344-1
pmc: PMC10173531
doi:
Substances chimiques
Culture Media, Conditioned
0
Brain-Derived Neurotrophic Factor
0
Vascular Endothelial Growth Factor A
0
Oxygen
S88TT14065
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
128Informations de copyright
© 2023. The Author(s).
Références
Stem Cells Transl Med. 2016 Apr;5(4):464-75
pubmed: 26956208
CNS Neurosci Ther. 2021 Nov;27(11):1300-1312
pubmed: 34346167
Stem Cells Int. 2020 Aug 11;2020:8837654
pubmed: 33953753
Toxicol Sci. 2020 Mar 1;174(1):147-158
pubmed: 31841155
Cytotechnology. 2015 Dec;67(6):1073-84
pubmed: 24798810
Lancet Neurol. 2021 Nov;20(11):917-929
pubmed: 34687636
Transl Neurosci. 2021 Dec 17;12(1):561-572
pubmed: 35003786
Biores Open Access. 2016 Aug 01;5(1):201-11
pubmed: 27588220
Cell Death Dis. 2021 Apr 6;12(4):357
pubmed: 33824286
J Cereb Blood Flow Metab. 2015 Jan;35(1):121-30
pubmed: 25370861
Cold Spring Harb Protoc. 2013 Sep 01;2013(9):810-4
pubmed: 24003197
Cell Mol Neurobiol. 2012 May;32(4):567-76
pubmed: 22290155
Stem Cell Res Ther. 2014 May 06;5(3):63
pubmed: 24887516
Oxid Med Cell Longev. 2013;2013:367206
pubmed: 24454980
Adv Sci (Weinh). 2021 Feb 24;8(7):2002944
pubmed: 33854883
Front Immunol. 2021 Aug 26;12:711362
pubmed: 34512632
Cells. 2021 Dec 06;10(12):
pubmed: 34943941
Cells. 2019 Nov 23;8(12):
pubmed: 31771176
Development. 1989 Mar;105(3):595-603
pubmed: 2558873
Cytotherapy. 2019 Oct;21(10):1019-1024
pubmed: 31526643
Biotechnol J. 2018 Feb;13(2):
pubmed: 29334181
Cell Tissue Bank. 2019 Jun;20(2):153-161
pubmed: 30852701
Nat Commun. 2021 Apr 15;12(1):2265
pubmed: 33859199
Stem Cells Dev. 2018 May 1;27(9):612-623
pubmed: 29630447
Stem Cell Rev Rep. 2022 Jun;18(5):1525-1545
pubmed: 35344199
J Biol Chem. 1999 Aug 6;274(32):22569-80
pubmed: 10428835
Neural Regen Res. 2019 Apr;14(4):597-604
pubmed: 30632499
Sci Rep. 2020 Mar 9;10(1):4290
pubmed: 32152403
Dev Neurosci. 2019;41(1-2):79-93
pubmed: 31167194
Neurosci Lett. 2010 Mar 19;472(2):94-8
pubmed: 20117176
Neural Regen Res. 2022 Nov;17(11):2376-2380
pubmed: 35535874
J Neurotrauma. 2020 Feb 1;37(3):431-440
pubmed: 31215324
Int J Mol Sci. 2020 Nov 27;21(23):
pubmed: 33261156
Mol Neurobiol. 2019 Oct;56(10):6902-6927
pubmed: 30941733
Neurosignals. 2005;14(5):207-21
pubmed: 16301836
Int J Mol Sci. 2021 Dec 16;22(24):
pubmed: 34948330
Exp Mol Med. 2010 Aug 31;42(8):583-95
pubmed: 20644345
Stem Cells Dev. 2013 Jan 15;22(2):330-9
pubmed: 22920587
Circulation. 2004 Mar 16;109(10):1292-8
pubmed: 14993122
Stem Cells Transl Med. 2021 Jul;10(7):1008-1020
pubmed: 33586908
Stem Cells Dev. 2016 Jul 15;25(14):1073-83
pubmed: 27226274
Front Cell Dev Biol. 2021 Aug 18;9:661532
pubmed: 34490235
Stem Cells. 2016 Mar;34(3):614-26
pubmed: 26700612
Glia. 2018 Jan;66(1):145-160
pubmed: 28940767
Stem Cell Res Ther. 2021 Nov 4;12(1):565
pubmed: 34736534
World J Stem Cells. 2014 Jul 26;6(3):256-65
pubmed: 25126376
Curr Stem Cell Res Ther. 2010 Jun;5(2):103-10
pubmed: 19941460
J Vis Exp. 2021 Mar 10;(169):
pubmed: 33779597
Front Cell Dev Biol. 2021 Jun 09;9:683609
pubmed: 34179015
PLoS One. 2013;8(4):e60254
pubmed: 23577097
Ann Med Surg (Lond). 2021 Jun 09;67:102482
pubmed: 34168873
Front Neurol. 2018 Jun 15;9:466
pubmed: 29963009
Int J Immunopathol Pharmacol. 2014 Jul-Sep;27(3):391-402
pubmed: 25280030
Cell Biosci. 2021 Nov 2;11(1):187
pubmed: 34727974
Stem Cells. 2017 Aug;35(8):1867-1880
pubmed: 28589621
Glia. 2020 May;68(5):898-917
pubmed: 31755592
Int J Mol Sci. 2018 Jul 27;19(8):
pubmed: 30060511
Cells. 2022 Mar 10;11(6):
pubmed: 35326396
Biomed Res Int. 2014;2014:965849
pubmed: 25530971
Cytotherapy. 2014 Oct;16(10):1336-44
pubmed: 24927715
PLoS One. 2014 Oct 07;9(10):e109305
pubmed: 25290916
Int J Mol Sci. 2017 Aug 25;18(9):
pubmed: 28841158
Biomolecules. 2021 Jun 22;11(7):
pubmed: 34206204
Growth Factors. 2004 Sep;22(3):123-31
pubmed: 15518235
Molecules. 2020 Jan 23;25(3):
pubmed: 31979414
Dis Model Mech. 2017 May 1;10(5):671-678
pubmed: 28237964
Exp Neurol. 2022 Jan;347:113895
pubmed: 34653510
Mol Cell Neurosci. 2004 Feb;25(2):252-62
pubmed: 15019942
Signal Transduct Target Ther. 2022 Mar 21;7(1):92
pubmed: 35314676
Front Endocrinol (Lausanne). 2018 Aug 30;9:503
pubmed: 30214428